This was 1 year ago
LocationBrussels
This conference, organised by the Commission, will bring together climate change & health researchers, funders and policymakers to reflect on the current challenges and needs for research in this area. Additionally, the conference will support the launch of a strategic research and innovation agenda identifying the priority topics for the years to come.
The conference will focus on four themes:
- Short and long-term impacts from climate change
- Climate change in the context of other environmental stressors
- Climate change and the health sector
- A global research agenda on climate change and health
The conference will also include an exhibition space. Information on calls for poster submissions will be available soon.
Registration is not open yet. You can already show your interest through pre-registration.
More information, the detailed agenda and registration (coming soon) on the dedicated Commission webpage.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.